Unilever is to buy GlaxoSmithKline's Indian Horlicks nutrition business for around $3.8 billion, boosting the consumer goods group's position in a key emerging market. The deal, announced on Monday, marks a further step by drug maker GSK to streamline its business and follows a competitive auction in which Unilever saw off rival Nestle, as well as earlier interest from Coca-Cola. The transaction covers GSK's health food and drinks portfolio in India, Bangladesh and 20 other predominantly Asian markets. The main asset being sold is GSK's 72.5 per cent stake in GlaxoSmithKline Consumer Healthcare.
Unilever said the 3.3 billion euros ($3.75 billion) it was paying would be paid in cash and shares in its subsidiary in India, Hindustan Unilever Limited (HUL).
GSK said its net proceeds from the deal, after tax and hedging costs, were expected to be around 2.4 billion pounds ($3.1 billion).
Following the closure of the deal, GSK will own approximately 5.7 per cent of HUL, which the British drug maker intends to sell down in tranches.
The price being paid for the GSK business, which includes the popular malt-based drinks Horlicks and Boost, is broadly in line with expectations. People familiar with the process had told Reuters it was likely to be for less than $4 billion.
Horlicks comfortably dominates the health-drinks market in India and Unilever is expected to try and give it a fresh lease of life, following a slowdown in sales growth in recent years.
GSK's decision to sell the business follows its $13 billion acquisition of Novartis's stake in the two groups' consumer health joint venture earlier this year. GSK said at the time that selling Horlicks could support the funding of the Novartis buyout.
Shares in HUL rose as much as 2.8 per cent to touch an intraday high of Rs 1,802.90 apiece on the NSE, whose benchmark index Nifty was flat in afternoon.
($1 = 0.8805 euros = 0.7814 pounds)